Treatment for major depressive disorder (MDD) involves a range of safe and effective therapies, many of which are available as inexpensive generics. Agents for treating MDD span multiple drug classes, and while selective serotonin reuptake inhibitors (SSRIs) and serotonin \/ norepinephrine reuptake inhibitors (SNRIs) are considered standards of care, branded therapies, including Trintellix (Lundbeck \/ Takeda\u2019s vortioxetine), Rexulti (Lundbeck \/ Otsuka\u2019s brexpiprazole), and Spravato (Janssen Pharmaceuticals\u2019 esketamine) are important treatment alternatives, particularly for treatment-resistant patients. Treatment is often a trial-and-error process owing to the heterogeneous nature of the patient population and the multitude of drugs available to treat depressive symptoms. As such, treatment of MDD is highly individualized and thus complex; therefore, a solid understanding of drivers of physicians\u2019 prescribing decisions is essential to assess opportunity in this highly prevalent indication.<\/p>\n
QUESTIONS ANSWERED<\/strong><\/p>\n \u00b7 What are the drivers and constraints influencing physicians\u2019 treatment decisions for MDD? How are patients being treated across different lines of therapy?<\/p>\n \u00b7 What drives switching to and from key brands such as Trintellix or Rexulti? How are physicians using Spravato to manage their MDD patients?<\/p>\n \u00b7 To what extent is polypharmacy prescribed for MDD in the United States, and what factors influence physicians\u2019 decision to use polypharmacy?<\/p>\n \u00b7 How has the use of key MDD therapies changed in the past year, and what changes do physicians expect in their prescribing of these drugs in one year?<\/p>\n PRODUCT DESCRIPTION<\/strong><\/p>\n Current Treatment: Physician Insights provides physician insights on treatment dynamics, prescribing behavior, and drivers of brand use so that marketers can create specific messaging around these treatment dynamics to more effectively increase or defend their market position.<\/p>\n Markets covered:<\/strong> United States<\/p>\n Primary research:<\/strong> Survey of 51 U.S. primary care physicians and 50 U.S. psychiatrists.<\/p>\n Key drugs:<\/strong> Aripiprazole (Abilify, generics), Latuda, Rexulti, Spravato, Trintellix, Vraylar<\/p>\n KEY INSIGHTS PROVIDED<\/strong><\/p>\n Factors influencing disease management and treatment decisions<\/p>\n Drivers and constraints of treatment selection<\/p>\n Physician-reported treatment practices and brand-level patient shares<\/p>\n Rationale for changes in treatment approach<\/p>\n Physician insight on persistency and compliance<\/p>\n Physician-reported recent\/anticipated changes in brand usage or treatment approach<\/p>\n","protected":false},"template":"","class_list":["post-389948","report","type-report","status-publish","hentry","report-gateway-biopharma","biopharma-therapy-areas-major-depressive-disorder","biopharma-therapy-areas-unipolar-depression","biopharma-product-treatment-algorithms-claims-data-analysis","biopharma-geography-us","biopharma-date-950"],"acf":[],"publishpress_future_workflow_manual_trigger":{"enabledWorkflows":[]},"_links":{"self":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389948","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report"}],"about":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/types\/report"}],"version-history":[{"count":1,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389948\/revisions"}],"predecessor-version":[{"id":393073,"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/report\/389948\/revisions\/393073"}],"wp:attachment":[{"href":"https:\/\/clarivate.com\/life-sciences-healthcare\/wp-json\/wp\/v2\/media?parent=389948"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}